Target intelligence / Profile preview

SNARE protein (presynaptic terminal) (SNARE (presynaptic))

Target
SNARE (presynaptic)
Molecular classification
Membrane protein, Vesicle fusion machinery, Other
01

Overview

SNARE proteins at the presynaptic terminal are a conserved family of membrane proteins critical for the fusion of synaptic vesicles with the presynaptic membrane, mediating neurotransmitter release and fast synaptic communication[1][2][3][5][6]. The canonical presynaptic SNARE complex consists of syntaxin-1 (plasma membrane, t-SNARE), SNAP-25 (plasma membrane, t-SNARE), and synaptobrevin/VAMP (vesicle membrane, v-SNARE), whose interactions physically pull the vesicle and plasma membranes together to enable rapid, calcium-triggered fusion during exocytosis[1][2][3][5][6]. SNARE function is tightly controlled by accessory proteins (Munc18, synaptotagmin, complexin), and dysregulation or mutation is implicated in schizophrenia, autism spectrum disorders, and neurodegenerative diseases including Parkinson’s disease[1][3]. Therapeutically, SNAREs are targeted by botulinum and tetanus neurotoxins, which cleave specific SNARE family members, thereby blocking neurotransmitter release and producing local paralysis[2][7]. Given their fundamental role in membrane fusion across cell types, systemic SNARE inhibition carries significant safety risks.

Other names
Soluble N-ethylmaleimide-sensitive factor attachment protein receptorSNARE complexVesicle-fusion protein
02

Mechanism of action

Inhibition of SNARE complex assembly (neurotoxins), Cleavage of SNARE proteins (neurotoxins), Modulation of vesicle fusion

03

Biological functions

Neurotransmitter releaseSynaptic vesicle exocytosisMembrane fusionRegulation of synaptic plasticityHormone/growth factor transport
04

Disease associations

Neurodegenerative diseaseNeurodevelopmental disorderPsychiatric disorderOther
05

Safety considerations

Broad essentiality in cellular vesicle trafficking (high risk of systemic side effects)Irreversible blockade can lead to paralysis (as with toxins)Off-target effects in non-neural tissues
06

Interacting drugs

Botulinum neurotoxins (BoNT/A, BoNT/B)

1 more in the full profile.

07

Biomarkers

SNAP-25 mRNA/protein levels in schizophrenia and autism spectrum disorderSNARE complex mutations for neurological diseaseSNAP-25 polymorphisms

Beyond the preview

Go deeper on SNARE protein (presynaptic terminal) (SNARE (presynaptic)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNARE protein (presynaptic terminal) (SNARE (presynaptic)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call